Affiliations
AffiliationItem in Clipboard
Adenoma detection rate and risk of colorectal cancer and deathDouglas A Corley et al. N Engl J Med. 2014.
. 2014 Apr 3;370(14):1298-306. doi: 10.1056/NEJMoa1309086. Authors Douglas A Corley 1 , Christopher D Jensen, Amy R Marks, Wei K Zhao, Jeffrey K Lee, Chyke A Doubeni, Ann G Zauber, Jolanda de Boer, Bruce H Fireman, Joanne E Schottinger, Virginia P Quinn, Nirupa R Ghai, Theodore R Levin, Charles P Quesenberry AffiliationItem in Clipboard
AbstractBackground: The proportion of screening colonoscopic examinations performed by a physician that detect one or more adenomas (the adenoma detection rate) is a recommended quality measure. However, little is known about the association between this rate and patients' risks of a subsequent colorectal cancer (interval cancer) and death.
Methods: Using data from an integrated health care delivery organization, we evaluated the associations between the adenoma detection rate and the risks of colorectal cancer diagnosed 6 months to 10 years after colonoscopy and of cancer-related death. With the use of Cox regression, our estimates of attributable risk were adjusted for the demographic characteristics of the patients, indications for colonoscopy, and coexisting conditions.
Results: We evaluated 314,872 colonoscopies performed by 136 gastroenterologists; the adenoma detection rates ranged from 7.4 to 52.5%. During the follow-up period, we identified 712 interval colorectal adenocarcinomas, including 255 advanced-stage cancers, and 147 deaths from interval colorectal cancer. The unadjusted risks of interval cancer according to quintiles of adenoma detection rates, from lowest to highest, were 9.8, 8.6, 8.0, 7.0, and 4.8 cases per 10,000 person-years of follow-up, respectively. Among patients of physicians with adenoma detection rates in the highest quintile, as compared with patients of physicians with detection rates in the lowest quintile, the adjusted hazard ratio for any interval cancer was 0.52 (95% confidence interval [CI], 0.39 to 0.69), for advanced-stage interval cancer, 0.43 (95% CI, 0.29 to 0.64), and for fatal interval cancer, 0.38 (95% CI, 0.22 to 0.65). Each 1.0% increase in the adenoma detection rate was associated with a 3.0% decrease in the risk of cancer (hazard ratio, 0.97; 95% CI, 0.96 to 0.98).
Conclusions: The adenoma detection rate was inversely associated with the risks of interval colorectal cancer, advanced-stage interval cancer, and fatal interval cancer. (Funded by the Kaiser Permanente Community Benefit program and the National Cancer Institute.).
FiguresFigure 1. Colonoscopic Examinations Performed by 136…
Figure 1. Colonoscopic Examinations Performed by 136 Gastroenterologists
ADR denotes adenoma detection rate, CRC colorectal…
Figure 1. Colonoscopic Examinations Performed by 136 GastroenterologistsADR denotes adenoma detection rate, CRC colorectal cancer, and KPNC Kaiser Permanente Northern California.
Figure 2. Hazard Ratios for Colorectal Cancer,…
Figure 2. Hazard Ratios for Colorectal Cancer, According to Quintile of Adenoma Detection Rates
Data…
Figure 2. Hazard Ratios for Colorectal Cancer, According to Quintile of Adenoma Detection RatesData were adjusted for sex, age, Charlson comorbidity index score, and indication for colonoscopy, with clustering according to physician. Vertical lines indicate 95% confidence intervals. HR denotes hazard ratio.
Similar articlesCross AJ, Robbins EC, Pack K, Stenson I, Kirby PL, Patel B, Rutter MD, Veitch AM, Saunders BP, Little M, Gray A, Duffy SW, Wooldrage K. Cross AJ, et al. Health Technol Assess. 2022 May;26(26):1-156. doi: 10.3310/OLUE3796. Health Technol Assess. 2022. PMID: 35635015 Free PMC article.
Schottinger JE, Jensen CD, Ghai NR, Chubak J, Lee JK, Kamineni A, Halm EA, Sugg-Skinner C, Udaltsova N, Zhao WK, Ziebell RA, Contreras R, Kim EJ, Fireman BH, Quesenberry CP, Corley DA. Schottinger JE, et al. JAMA. 2022 Jun 7;327(21):2114-2122. doi: 10.1001/jama.2022.6644. JAMA. 2022. PMID: 35670788 Free PMC article.
Kaminski MF, Wieszczy P, Rupinski M, Wojciechowska U, Didkowska J, Kraszewska E, Kobiela J, Franczyk R, Rupinska M, Kocot B, Chaber-Ciopinska A, Pachlewski J, Polkowski M, Regula J. Kaminski MF, et al. Gastroenterology. 2017 Jul;153(1):98-105. doi: 10.1053/j.gastro.2017.04.006. Epub 2017 Apr 17. Gastroenterology. 2017. PMID: 28428142
Rex DK. Rex DK. Am J Gastroenterol. 1995 Mar;90(3):353-65. Am J Gastroenterol. 1995. PMID: 7872270 Review.
Walshe M, Moran R, Boyle M, Cretu I, Galvin Z, Swan V, Trikovic J, Farrell MP, Foy S, O'Brien L, Leyden J, Mulligan N, Fenlon H, Gallagher DJ, MacMathúna P. Walshe M, et al. Cancer Epidemiol. 2017 Oct;50(Pt A):30-38. doi: 10.1016/j.canep.2017.07.002. Epub 2017 Aug 4. Cancer Epidemiol. 2017. PMID: 28783501 Review.
Stoffel EM, Erichsen R, Frøslev T, Pedersen L, Vyberg M, Koeppe E, Crockett SD, Hamilton SR, Sørensen HT, Baron JA. Stoffel EM, et al. Gastroenterology. 2016 Nov;151(5):870-878.e3. doi: 10.1053/j.gastro.2016.07.010. Epub 2016 Jul 19. Gastroenterology. 2016. PMID: 27443823 Free PMC article.
Wang D, Xu Q, Dai S, Zhang Y, Ding F, Ji L. Wang D, et al. Prev Med Rep. 2024 Feb 1;39:102636. doi: 10.1016/j.pmedr.2024.102636. eCollection 2024 Mar. Prev Med Rep. 2024. PMID: 38333601 Free PMC article.
Singh H, Graber ML, Hofer TP. Singh H, et al. J Patient Saf. 2019 Dec;15(4):311-316. doi: 10.1097/PTS.0000000000000338. J Patient Saf. 2019. PMID: 27768655 Free PMC article.
Bretagne JF, Hamonic S, Piette C, Viel JF, Bouguen G. Bretagne JF, et al. World J Gastroenterol. 2016 Oct 14;22(38):8549-8557. doi: 10.3748/wjg.v22.i38.8549. World J Gastroenterol. 2016. PMID: 27784967 Free PMC article.
Ashat M, Klair JS, Singh D, Murali AR, Krishnamoorthi R. Ashat M, et al. Endosc Int Open. 2021 Apr;9(4):E513-E521. doi: 10.1055/a-1341-0457. Epub 2021 Mar 17. Endosc Int Open. 2021. PMID: 33816771 Free PMC article. Review.
RetroSearch is an open source project built by @garambo | Open a GitHub Issue
Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo
HTML:
3.2
| Encoding:
UTF-8
| Version:
0.7.3